GRAIL, Inc. (NASDAQ:GRAL – Get Free Report) CFO Aaron Freidin sold 3,000 shares of the business’s stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $107.62, for a total value of $322,860.00. Following the transaction, the chief financial officer directly owned 222,364 shares of the company’s stock, valued at $23,930,813.68. The trade was a 1.33% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Aaron Freidin also recently made the following trade(s):
- On Monday, October 5th, Aaron Freidin sold 23,619 shares of GRAIL stock. The stock was sold at an average price of $146.39, for a total transaction of $3,457,585.41.
- On Monday, September 21st, Aaron Freidin sold 4,100 shares of GRAIL stock. The shares were sold at an average price of $93.34, for a total value of $382,694.00.
- On Thursday, August 27th, Aaron Freidin sold 7,900 shares of GRAIL stock. The shares were sold at an average price of $85.01, for a total value of $671,579.00.
GRAIL Trading Down 8.9%
NASDAQ GRAL traded down $10.29 during trading hours on Monday, reaching $105.60. 792,617 shares of the stock traded hands, compared to its average volume of 936,290. The stock has a 50 day simple moving average of $121.96 and a two-hundred day simple moving average of $79.74. GRAIL, Inc. has a 1 year low of $41.50 and a 1 year high of $166.48.
GRAIL (NASDAQ:GRAL – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($2.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.45) by $0.24. The firm had revenue of $37.53 million during the quarter, compared to analyst estimates of $44.21 million. GRAIL had a negative return on equity of 16.13% and a negative net margin of 243.80%. Research analysts forecast that GRAIL, Inc. will post -9.11 EPS for the current fiscal year.
Institutional Investors Weigh In On GRAIL
A number of hedge funds and other institutional investors have recently modified their holdings of GRAL. Primecap Management Co. CA bought a new stake in GRAIL in the second quarter valued at approximately $148,836,000. Bank of America Corp DE purchased a new stake in shares of GRAIL during the second quarter valued at approximately $49,389,000. BlackRock Inc. boosted its stake in shares of GRAIL by 20.5% during the second quarter. BlackRock Inc. now owns 3,577,075 shares of the company’s stock valued at $244,207,000 after purchasing an additional 608,539 shares during the period. State Street Corp grew its holdings in shares of GRAIL by 26.1% in the second quarter. State Street Corp now owns 2,385,514 shares of the company’s stock worth $162,859,000 after purchasing an additional 493,621 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of GRAIL by 88.5% in the first quarter. Dimensional Fund Advisors LP now owns 408,650 shares of the company’s stock worth $21,104,000 after purchasing an additional 191,857 shares during the last quarter.
Analyst Ratings Changes
GRAL has been the subject of several research reports. Robert W. Baird upped their target price on GRAIL from $96.00 to $118.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 22nd. Morgan Stanley lifted their price target on shares of GRAIL from $60.00 to $120.00 and gave the stock an “equal weight” rating in a research note on Monday, October 12th. Wall Street Zen raised shares of GRAIL from a “sell” rating to a “hold” rating in a research note on Sunday, September 13th. Mizuho boosted their price objective on shares of GRAIL from $65.00 to $100.00 and gave the stock a “neutral” rating in a report on Friday, September 25th. Finally, Canaccord Genuity Group upped their price objective on shares of GRAIL from $80.00 to $150.00 and gave the company a “buy” rating in a research note on Monday, September 28th. Five investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $128.80.
Get Our Latest Analysis on GRAL
GRAIL Company Profile
GRAIL, Inc. is a healthcare company developing blood-based tests for the early detection of multiple cancers. Its approach analyzes patterns in cell-free DNA, including DNA methylation signals, to help identify a possible cancer signal and predict its origin in the body. GRAIL’s flagship product is Galleri, a multi-cancer early detection test intended for use alongside—not as a replacement for—recommended cancer screening. The company also conducts clinical research to evaluate the test and advance its early-detection technology.
Recommended Stories
- Five stocks we like better than GRAIL
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for GRAIL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRAIL and related companies with MarketBeat.com's FREE daily email newsletter.
